ClinicalTrials.gg
Active, not recruitingNCT06524947Updated Jan 23, 2025

Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

A Phase 3 interventional study of quadrivalent recombinant norovirus vaccine (Pichia pastoris) and quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo in Acute Gastroenteropathy Due to Norovirus, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Active, not recruiting at 3 sites in China. Open to participants aged 6 Weeks to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,600
Allocation
Randomized
Ages
6 Weeks to 13 Years
Sex
All
01

Study summary

The purpose of the research is to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pastoris) in people aged 6 weeks to 13 years.A total of 6600 infants and children aged 6 weeks to 13 years old were enrolled in this study, which were divided into 3 age groups: 1400 children (6-13 years old), 2200 toddler (2-5 years old), and 3000 infants (6-23 months old).Subjects of all ages were randomly assigned to the test group and the control group in a 1:1 ratio.All subjects received 3 doses of the experimental vaccine at 30 day intervals.

Read the detailed description

Overall design: A multicenter, randomized, double-blind, placebo-controlled trial was designed.

The purpose of the research is to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pastoris) in people aged 6 weeks to 13 years.A total of 6600 infants and children aged 6 weeks to 13 years old were enrolled in this study, which were divided into 3 age groups: 1400 children (6-13 years old), 2200 toddler (2-5 years old), and 3000 infants (6-23 months old).Subjects of all ages were randomly assigned to the test group and the control group in a 1:1 ratio.All subjects received 3 doses of the experimental vaccine at 30 day intervals.

Protective effectiveness evaluation:All subjects entered the observation period 7 days after completing the first dose of immunization. Stool and/or vomit samples (if applicable) from all AGE cases occurring during the observation period were collected and AGE caused by Norovirus was identified by PCR.Primary protective efficacy was calculated using data from primary endpoint cases that occurred between 7 days after completion of full immunization and the end of the observation period.

Immunogenicity evaluation:For the immunogenic subgroup of subjects (120 subjects before the study number of each age group in a clinical trial site, a total of 360 subjects), blood samples were collected before the first dose of immunization, 31 days after the second dose of immunization, 31 days, 180 days, 1 year and 2 years after the total immunization, and blood samples were 2.5\~3.0ml each time.It is used to detect anti-norovirus IgG antibody, tissue Blood group antigen (HBGA) blocking antibody, and to detect the immunogenicity of anti-norovirus.

Safety evaluation:Adverse events (AE) and serious adverse events (SAE) : All enrolled subjects collected AE 30 minutes after each dose of vaccine, enlisted AE 0-7 days, non-enlisted AE 0-30 days, and SAE from the first dose to 180 days after full immunization.

02

Conditions studied

  • Acute Gastroenteropathy Due to Norovirus

Keywords

  • prevention
03

In context

Lead sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. is the lead sponsor of 49 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.The subject's legal guardian agrees to participate in the trial (consent is also required for subjects 8 years of age and older), and can provide proof of legal identity, is fully informed and has signed an form, and understands and complies with the requirements of the trial protocol to participate in the follow-up visits.
  • 2.The age of the subjects on the day of enrollment is not less than 6 weeks old and not more than 13 years old, regardless of gender.
  • 3.Those younger than 12 months of age: 2.5kg ≤ birth weight ≤ 4.5kg, 37 weeks ≤ weeks of gestation ≤ 42 weeks, born in normal labor (excluding severe abnormal labor and history of severe asphyxia resuscitation).

Exclusion criteria

Exclusion Criteria:

  • 1.Allergic to or having a history of specific reactions to any component of the vaccine; Previous history of severe allergy to any vaccine or drug (such as anaphylactic shock, laryngeal edema, anaphylactic purpura, local anaphylactic necrosis reaction (Arthus reaction), dyspnea, angioneurotic edema, etc.); People with allergic constitution.
  • 2.A history of confirmed norovirus infection within 2 years.
  • 3.Have a history of any of the following diseases or are suffering from serious diseases: ① Abnormal coagulation function: such as leukemia, congenital or acquired coagulation factor deficiency, aplastic anemia, thrombocytopenia and receiving anticoagulation therapy; ② Diseases affecting local observation: such as rational jaundice; ③Diseases affecting immune function: a history of congenital or acquired immunodeficiency or disease; Uncontrolled lymphoproliferative diseases (such as chronic lymphocytic leukemia, Hodgkin's lymphoma, etc.); No spleen, or splenic surgery history, trauma history; ④Now suffering from infectious diseases: such as tuberculosis, viral hepatitis, etc; ⑤Neurological and psychiatric diseases: epilepsy, congenital brain hypoplasia, brain trauma, brain tumor, infection, brain nerve tissue damage caused by chemical and physical factors, etc., psychiatric history and family history; ⑥Other serious diseases that may interfere with the conduct or completion of the study: severe congenital malformations, severe developmental disorders, severe malnutrition, malignant tumors, congenital cardiovascular, liver, kidney diseases, etc.
  • 4.Received blood or blood-related products (other than immunoglobulin) within 1 month prior to enrollment; Long-term use of systemic or other immunomodulatory drugs within 3 months (defined as use for more than 14 days).
  • 5.Have participated or are participating in other clinical trials (including drugs, biologics, or devices) within 3 months prior to enrollment.
  • 6.The investigator believes that the subject has any disease or condition that could put the subject at risk, poor adherence or inability to complete the trial as required by the protocol, and conditions that interfere with the evaluation of vaccine response.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,600 participants (actual)

Study arms

  • Experimental
    Infant experimental group (6 weeks -23 months)

    At least 6 weeks old but less than 2 years old.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

  • Placebo comparator
    Infant placebo control group (6 weeks -23 months)

    At least 6 weeks old but less than 2 years old.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

  • Experimental
    Toddler experimental group (2-5 years old)

    At least 2 years old but less than 6 years old.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

  • Placebo comparator
    Toddler placebo control group (2-5 years old)

    At least 2 years old but less than 6 years old.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

  • Experimental
    Children experimental group (6-13 years old)

    At least 6 years of age but under 14 years of age.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris)

  • Placebo comparator
    Children placebo control group (6-13 years old)

    At least 6 years of age but under 14 years of age.

    Biological: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

Interventions

  • Biologicalquadrivalent recombinant norovirus vaccine (Pichia pastoris)

    Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval. Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate

  • Biologicalquadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo

    Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval. Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate

06

What researchers measure

Primary outcomes

  1. Protective efficacy against AGE caused by four genotypes of norovirus

    Protective efficacy against AGE caused by the four genotypes included in the prophylactic vaccine (GI.1, GII.3, GII.4, GII.17) (co-infections of rotavirus and adenovirus were excluded) after 7 days of full immunization until the end of the observation period.Protective efficacy = 1 - (person-years of incidence in the vaccine group/person-years of incidence in the placebo group) × 100%; person-years of incidence = (number of cases of AGE (excluding co-infections with rotavirus and adenovirus) caused by the four genotypes included in the vaccine (GI.1, GII.3, GII.4, and GII.17) after 7 days of 3 doses of the vaccine/number of person-years of observation) × 100%.

    Time frame: From 7 days after full immunization to 2 years after 7 days after after full immunization

  2. Geometric mean titers (GMT) of IgG antibody

    Geometric mean titers of IgG antibodies against norovirus (GI.1, GII.3, GII.4, GII.17) were measured at 31 days after 2 doses, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization.

    Time frame: 31 days after 2 doses, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization

  3. Geometric mean titers (GMT) of HBGA blocking antibody

    Geometric mean titers of HBGA blocking antibodies against norovirus (GI.1, GII.3, GII.4, GII.17) were measured at 31 days after 2 doses of immunization, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization.

    Time frame: at 31 days after 2 doses of immunization, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization

  4. Positive conversion rate of IgG antibodies

    Positive conversion rate of IgG antibody against norovirus (GI.1, GII.3, GII.4, GII.17) at 31 days after 2 doses, 31 days after full immunization, 180 days after full immunization, 1 year and 2 years after full immunization.

    Time frame: 31 days after 2 doses, 31 days after full immunization, 180 days after full immunization, 1 year and 2 years after full immunization

  5. Positive conversion rate of HBGA blocking antibody

    The positive conversion rate of HBGA blocking antibodies against norovirus (GI.1, GII.3, GII.4, GII.17) was measured at 31 days after 2 doses of immunization, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization.

    Time frame: 31 days after 2 doses of immunization, 31 days after full immunization, 180 days after full immunization, 1 year, and 2 years after full immunization

  6. Geometric mean titers Growth multiplier of IgG antibody

    Geometric mean titers Growth multiplier of IgG antibody at 31 days after 2 doses of immunization and at 31 days after full immunization.

    Time frame: at 31 days after 2 doses of immunization and at 31 days after full immunization

  7. Geometric mean titers Growth multiplier of HBGA blocking antibody

    Geometric mean titers Growth multiplier of HBGA blocking antibody at 31 days after 2 doses of immunization and at 31 days after full immunization.

    Time frame: at 31 days after 2 doses of immunization and at 31 days after full immunization

  8. Occurrence of any adverse event

    Occurrence of any adverse event within 30 minutes of each dose of vaccination.

    Time frame: within 30 minutes of each dose of vaccination

  9. Occurrence of recruited adverse event

    Occurrence of recruited adverse event between day 0 and day 7 after each dose of vaccination.

    Time frame: between day 0 and day 7 after each dose of vaccination

  10. Occurrence of non-recruited adverse event

    Occurrence of non-recruited adverse event between day 0 and day 30 after each dose of vaccination.

    Time frame: between day 0 and day 30 after each dose of vaccination

  11. Occurrence of serious adverse event

    Occurrence of serious adverse event from the first dose to 180 days after full immunization.

    Time frame: from the first dose to 180 days after full immunization

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 29, 2024
StartActual
Jul 27, 2024
Primary completionEst.
Mar 28, 2027
CompletionEst.
Mar 28, 2027
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06524947
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jul 27, 2024
Primary completion
Mar 28, 2027 (estimated)
Completion
Mar 28, 2027 (estimated)
Last update
Jan 23, 2025

Study contacts

teng huang, master
principal investigator · Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion